Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab.
- Citation:
- Clin Cancer Res vol 28 (8) 1690-1700
- Year:
- 2022
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- Alliance-data-source,-internal-user
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- Pharmas:
- Bristol Myers Squibb (BMS), Genentech, Pfizer, and Sanofi
- Grants:
- U10CA180821, U10CA180882, U24CA196171, P30CA014089, UG1CA180830, UG1CA233253, UG1CA233327, UG1CA233373, U10CA180820 (ECOG-ACRIN), U10CA180888 (SWOG)
- Corr. Author:
- Authors:
- Federico Innocenti Akram Yazdani Naim Rashid Xueping Qu Fang-Shu Ou Scott Van Buren Monica M Bertagnolli Omar Kabbarah Charles David Blanke Alan P Venook Heinz-Josef Lenz Benjamin G Vincent
- Networks:
- CA011, CA136, LAPS-MA036, LAPS-MN026, LAPS-NC007, OR013
- Study
- Alliance-A151813
- Multiple Studies, or Legacy Studies in Alliance Study:
- CALGB-80405
- Phases:
- N/A, 3
- Keywords: